<DOC>
	<DOCNO>NCT00295815</DOCNO>
	<brief_summary>This protocol test activity Enzastaurin vs. Lomustine treatment recurrent brain cancer ( specifically intracranial glioblastoma multiforme ) .</brief_summary>
	<brief_title>Enzastaurin Versus Lomustine Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>1 . Patient present histologically confirm diagnosis brain cancer ( specifically glioblastoma multiforme ) . 2 . Your cancer return follow therapy . 3 . Patient may undergo prior surgery remove cancer . 4 . Patient must able care self . 1 . Have second type cancer ( except adequately treat basal cell carcinoma skin ) . Patient another cancer past , must free cancer 2 year . 2 . Have receive treatment within last 30 day drug receive regulatory approval indication time entry . 3 . Patients receive medication seizure must discontinue 14 day prior enrol . 4 . Can blood thin medication study enrollment . 5 . Can medicine prevent cancer study enrollment . 6 . Patients allow enter study previously take Enzastaurin , Lomustine and/or Bevacizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>